Mass Tort Lawyer Fees

How mass tort lawyers charge: your own lawyer, your own contingency fee

A mass tort is not a class action, and the difference decides how you are charged. In a class action one court appoints counsel for an entire class and awards that firm a fee for the group; most class members never hire anyone and never sign anything. A mass tort works the other way round — you retain your own lawyer, sign your own contingency agreement, and own your own claim from start to finish.

Your case is then consolidated with others before a single judge, under the federal multidistrict litigation statute, for pretrial proceedings only. Consolidation does not merge the claims or pool the money. If the litigation does not resolve, your case can be sent back to the court where it was filed and tried on its own facts.

The fee itself looks like any other injury contingency: nothing up front, commonly a third of what you personally recover, stepping toward 40% if your case is actually tried. Many MDL courts cap the total contingency by order, often at around a third, so a step-up clause in your agreement can be overridden by the court.

Two things make the arithmetic different from a single-plaintiff case, and both get their own section below: a court-ordered common benefit holdback that pays the lawyers doing the work for everyone, and liens. Before you sign, ask whether the percentage is taken on the gross recovery or after costs are repaid, and who absorbs the holdback. Get both answers in the fee agreement rather than in conversation.

Attorney fees vs. case costs when the costs are shared

The attorney fee is the percentage, and nothing else. Case costs are the money spent proving the claim, and in a mass tort most of that money is spent once, for everybody: general-causation experts, review of the defendant’s internal documents, regulatory history, and the science the company itself generated.

That shared structure cuts both ways. Per claimant the costs are low compared with a standalone product liability case, where one plaintiff has to fund an entire engineering and medical work-up alone. But the shared spend is enormous in absolute terms, and it is recovered through the common benefit assessment rather than billed to you line by line.

You still carry case-specific costs: pulling your pharmacy, implant, purchase or employment records, obtaining your treating physicians’ files, a case-specific expert report where the program requires one, and your deposition if you are selected for workup. These typically run from a few hundred dollars to a few thousand — a fraction of what a case tried alone consumes.

Ask three questions about ordering, because each one moves your net. Is the fee calculated on the gross recovery or after costs are repaid, and are shared costs charged to you again on top of the holdback or only once? If the litigation collapses and nothing is recovered, who absorbs what has already been spent — reputable firms do, but the clause still belongs in writing.

The common benefit fund: the deduction almost nobody expects

A handful of firms do the work that benefits every claimant in the litigation. They take the corporate depositions, fund the general-causation experts, brief the dispositive motions and try the bellwethers, and the court appoints them as leadership counsel. They are not paid by the thousands of claimants they never represented; they are paid out of a common benefit fund.

The court creates that fund by ordering a holdback — a percentage of every settlement or judgment in the litigation, often somewhere in the 6% to 12% range, and sometimes split into a separate fee component and cost component. The money is withheld from the gross recovery before anything is distributed, usually through a qualified settlement fund, and the court later divides it among the leadership firms on application.

Whether that holdback reduces your lawyer’s fee or your own net is the question that matters, and the answer is not uniform. Some courts order the assessment to be absorbed out of the individual attorney’s contingency share, so your net is untouched. Others assess the gross recovery, which means it comes off the money in addition to your lawyer’s percentage.

Almost no claimant learns any of this exists until it appears as a line on a settlement statement. Ask at the first meeting which way your litigation handles it, and ask for that answer in the fee agreement. On a mid-tier award the gap between the two answers is thousands of dollars of your money.

Liens: why the gross award is not what reaches you

A mass tort settlement is payment for an injury somebody else already paid to treat, so the payers want their money back. Medicare and Medicaid hold statutory reimbursement rights, a self-funded health plan usually holds a contractual one, the VA and military health coverage can assert theirs, and a hospital may have filed a lien directly against the claim.

Because a program resolves thousands of claims at once, lien work is industrialised. A court-appointed lien administrator negotiates in bulk with Medicare’s recovery contractor and the larger plans, and a holdback sits in escrow until your individual file clears. That is usually faster and cheaper than resolving a lien alone, but it is also the stage that most often explains why an award announced in the spring is paid in the autumn.

The amounts are more negotiable than claimants expect. Conditional payments are routinely reduced for unrelated treatment and for procurement costs, plans differ enormously in how much leverage they actually hold, and every dollar knocked off a lien reaches you dollar for dollar. How that negotiation works is covered in medical liens.

Two practical points. Ask whether lien resolution is inside the contingency fee or charged separately, because firms genuinely differ. And disclose every payer who touched the injury, including coverage you have since left — a plan discovered after distribution is the one thing that can claw money back from you personally.

How the litigation actually runs: fact sheets, bellwethers, remand

The first thing asked of you is a plaintiff fact sheet: a long sworn questionnaire about your use of the product, your treatment, your other conditions and your work history, with records attached. It is a discovery obligation rather than paperwork, and claims are dismissed for failing to complete it on time. Proof that you actually used the product — a pharmacy record, an implant sticker, a surgical report, a purchase or service record — is what keeps a claim alive at all.

Meanwhile the litigation fights the questions common to everyone: whether the product can cause this injury, what the company knew and when, and whether federal regulation preempts the claim. Those are decided once, for the whole group. A ruling against the plaintiffs on general causation can end an entire litigation; a ruling for them is what brings a defendant to the table.

A small number of representative cases are then selected as bellwethers and tried to verdict. Nobody else is bound by those results, but both sides price the inventory from them, and a run of plaintiff verdicts is usually what precedes a settlement program.

Expect years rather than months, and expect long stretches where nothing visible happens in your file. Filing is quick; general-causation briefing, bellwether trials, a negotiated program and then lien clearance are not. Ask what stage the litigation has reached before concluding that your own case has stalled.

Settlement matrices and what an individual claim is worth

Mass torts usually end in a settlement program rather than thousands of separate negotiations. A matrix assigns points or tiers from a small set of objective facts: which injury you suffered, how well it is documented, how long and how recently you used the product, your age, and sometimes your competing risk factors. Those inputs produce a scheduled amount rather than a negotiated one.

The method is efficient and deliberately blunt. It rewards documentation over advocacy, so a well-papered claim with a clear diagnosis and clean proof of use lands a tier above an identical injury with thin records. It also compresses the range: most claimants land in the middle, and both extremes are narrower than a jury would produce.

That is exactly why the fee figures on this page sit below a single-plaintiff product liability case even though the litigation itself is far larger. A matrix pays a moderate amount to very many people. A standalone product or medical malpractice claim is worked up and valued entirely on its own facts, and its top end is not bounded by a schedule.

If your injury is catastrophic or atypical, opting out and litigating individually can be worth considerably more — and can also recover nothing. That is a real judgment call with a hard deadline attached, and it is the decision where your own lawyer’s independent advice earns its keep. Ask for that advice in writing.

Why your state matters: the deadline, and whether you can recover at all

Start with what your location does not change. A settlement matrix is national — your tier does not rise because you live in an expensive metro, and a mid-tier claimant in San Francisco is offered the same scheduled amount as one in rural Ohio. The contingency percentage barely moves either.

What your state controls comes earlier and matters more: whether you have a claim at all. The statute of limitations is state law, the periods differ by claim type, and so does the discovery rule that decides when the clock started — at the injury, at the diagnosis, or when you could reasonably have connected the two. Mass torts turn on that rule, because the harm often surfaces long after the exposure.

Fault apportionment is state law too. California and New York apply pure comparative fault, so a share of blame reduces an award without barring it; Virginia and Maryland still apply contributory negligence, where even a small share can defeat a negligence count outright. Several states also cap non-economic damages, and the cap where your case sits travels with it.

The practical consequence is that the first question is local even though the settlement is not. Find out what period applies to your claim type in your state, and whether it has already run, before spending time on anything else. That is a question for a lawyer licensed where you live, not for a national advertisement.

Choosing a mass tort lawyer and keeping more of your recovery

Firstly, find out whether you are talking to a law firm at all. Mass tort advertising is an industry in its own right, and much of it is run by lead generators that collect your information and sell it on to firms — they are not your lawyers and owe you no duty of loyalty or confidentiality. Ask for the name of the attorney who would handle the case and the bar they are admitted to.

Secondly, expect the case to be referred, and do not fear the fee split. The firm whose advertisement you answered often sends the case to a firm that actually litigates in the MDL, and the two divide the fee under the ethics rules — out of the same percentage you already agreed to, so a referral does not increase your total fee. What it does change is who returns your calls, so ask who will be handling your file day to day.

Thirdly, compare the three terms that actually move your net rather than the headline percentage: gross or net calculation of the fee, who absorbs the common benefit holdback, and whether lien work sits inside the fee. Every firm offers a free consultation, so put the same three questions to two firms and compare the answers.

Finally, do the part only you can do. Find your proof of product use now, keep your treatment records together, answer the fact sheet fully and on time, and raise the deadline question at the very first call. A claim lost to the limitation period is the one outcome no fee structure can repair.